2' DEOXYCOFORMYCIN IN PATIENTS WITH HCL OR T-GAMMA LYMPHOPROLIFERATIVE DISORDER

目的：探讨脱氧共福霉素（dCF）治疗毛细胞白血病的临床疗效。 是作为一种挽救方案而写的， 在其他正在进行的临床研究分支中对干扰素有反应 协议. 我们还想测试这种药物在T-γ 淋巴增生性疾病，因为dCF已被发现有活性 在其他惰性T细胞疾病中。 目前已有9名患者接受治疗 在这个方案中，五个是毛细胞白血病，四个是T-γ 淋巴增生性疾病 所有患者均对 干扰素治疗，并有不同程度的外周血 血细胞减少症 在6名毛细胞白血病患者中， 3例部分应答，1例无应答，1例死于 难治性血小板减少症和弥漫性消化道出血 只有两剂dCF。 在五个T-γ的病人中 淋巴组织增生性疾病，两个有部分反应，两个 无反应者。 我们得出结论，DCF具有干扰素活性 耐药毛细胞白血病和一些T-γ 淋巴增生性疾病

This study of deoxycoformycin (dCF) in patients with hairy cell leukemia was written as a salvage protocol for patients who would progress or not respond to interferon in other ongoing Clinical Research Branch protocols. We also wanted to test the efficacy of this drug in T-gamma lymphoproliferative disorder since dCF had been found to have activity in other indolent T-cell diseases. Nine patients have now been treated on this protocol, five with hairy cell leukemia and four with T-gamma lymphoproliferative disorder. All patients were resistant to interferon-alpha treatments and had varying degrees of peripheral blood cytopenias. Of the six patients with hairy cell leukemia, there were three partial responses, one nonresponder and one patient who died of refractory thrombocytopenia and diffuse gastrointestinal bleeding after only two doses of dCF. Of the five patients with T-gamma lymphoproliferative disorder, two have had partial responses and two were non-responders. We conclude that dCF has activity in interferon resistant hairy cell leukemia and in some patients with T-gamma lymphoproliferative disorder.